CCEL - Dividend announcements

Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company", "Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced that the Company will not declare a quarterly cash dividend for the third quarter of fiscal 2025. This decision reflects lower-than-expected profitability. Cryo-Cell may or may not reinstate a dividend in future periods, and any future decisions regarding dividend declarations will be based on a variety of factors, including financial performance, capital requirements, and strategic priorities. For more information, please visit www.cryo-cell.com or contact Investor Relations at investors@cryo-cell.com. Abou

Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) ("Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that, as a result of the current economic environment and other capital allocation alternatives, its Board of Directors has approved the payment of a reduced, quarterly cash dividend of $0.15 per share of common stock to be paid to its shareholders of record as of the close of business on May 21, 2025. The dividend is expected to be paid on May 30, 2025. The Board of Directors will continue to evaluate the Company's dividend policy on a regular basis and may change such policy at any time. There is no assurance that

Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) ("Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that its Board of Directors has approved the payment of a quarterly cash dividend of $0.25 per share of common stock to be paid to its shareholders of record as of the close of business on February 14, 2025. The dividend is expected to be paid on February 28, 2025. The Board of Directors will continue to evaluate the Company's dividend policy on a regular basis and may change such policy at any time. There is no assurance that future dividends will be paid. The Company also announced that it has paused its strateg

Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) ("Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that its Board of Directors has approved the payment of a regular quarterly cash dividend at an initial rate of $0.25 per share of common stock to be paid to its shareholders of record as of the close of business on November 15, 2024. The dividend is expected to be paid on November 29, 2024. The Board of Directors plans to evaluate the dividend policy on a regular basis, considering the Company's earnings, cash flows, and alternative uses of and access to capital that may arise. Depending on these factors, future di

Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2024. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2024 were $8.07 million compared to $7.87 million for the third quarter of fiscal 2023. Net Income The Company reported net income for the three months ended August 31, 2024 of $1.05 million, or $0.13 per basic share and diluted share, compared to net income of $681,000, or $0.08 per basic and diluted share for the three months ended August 31, 2023. During the three months end

Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company" or "Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, today announced that its Board of Directors has authorized the spin-off of its newly formed subsidiary, Celle Corp., to the Cryo-Cell shareholders and to explore all strategic alternatives for Cryo-Cell (post spin-off) to maximize shareholder value, including, but not limited to, equity and/or debt financings and/or the possible sale or merger of the company. There is no assurance that such a transaction will take place. Celle Corp. was created to hold certain assets of Cryo-Cell not directly associated with the recurri

OLDSMAR, Fla., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) ("Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that its Board of Directors declares a one-time, special cash dividend of $0.90 per share of common stock to be paid to its shareholders of record as of the close of business on September 2, 2022. Cryo-Cell's Chairman of the Board and Co-CEO, David Portnoy, stated "Cryo-Cell's Board of Directors is pleased to reward its many long-time shareholders with this cash distribution while remaining committed to advancing cellular therapies using cord blood and c